COMMUNIQUÉS West-GlobeNewswire

Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease

11/06/2024 - 15:00

With current HLHS treatment, only 50-60% of infants survive to adolescence In ELPIS I Phase 1 clinical trial, children experienced 100% transplant-free survival up to five years of age after receiving Lomecel-B™ [...]

CanaQuest Announces Key Appointments to Team to Drive CQ-001 through Clinical Trials

11/06/2024 - 15:00

Appointee, formerly with GW Pharma (subsidiary) , brings extensive expertise in cannabinoid therapeutics, including the FDA-approved launch of cannabidiol (Epidiolex ® ) TORONTO, ON, June 11, 2024 (GLOBE NEWSWIRE) -- [...]

IntelGenx Announces Initiation of the Sale and Investment Solicitation Process

11/06/2024 - 14:52

MONTREAL, June 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “ Company ” or “ IntelGenx ” a subsidiary of IntelGenx Technologies Corp.) (OTCQB: IGXT; TSX: IGX), was granted protection pursuant to an order (as [...]

International Myeloma Foundation (IMF) to Honor 2024 Kyle and Durie Achievement Awardees, Dr. Shaji Kumar and Dr. Francesca Gay

11/06/2024 - 14:45

Awarding ceremonies to be held on June 11 at the 15th Annual IMWG Summit in Madrid, Spain MADRID, Spain, June 11, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) and the International Myeloma Working [...]

NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application

11/06/2024 - 14:44

TORONTO and HAIFA, Israel, June 11, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company developing [...]

NEXGEL and STADA Partner to Launch Leading European DAO Enzyme Supplement, Histasolv, in North America

11/06/2024 - 14:40

LANGHORNE, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content [...]

Sofwave Medical Receives Marketing Clearance in Canada for Pure Impact™ Strength and Muscle Toning Device

11/06/2024 - 14:33

– Approval by Health Canada regulatory authority immediately clears the way for Pure Impact™ with PlyoPulse™ device launch and commercialization in Canada – Canada Represents Another Substantial Market Opportunity for [...]

Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024

11/06/2024 - 14:30

CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President [...]

SeaStar Medical’s Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology

11/06/2024 - 14:30

DENVER, June 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on [...]

Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108

11/06/2024 - 14:30

PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of UC before year end [...]

Faraday Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 Iocyte AMI-3 Trial of FDY-5301

11/06/2024 - 14:30

2,300 patients in trial enrolled ahead of schedule 12-month follow up period underway, with topline data anticipated in 2H 2025 Trial designed with 90% power to detect a 30% reduction in the primary outcome of heart [...]

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

11/06/2024 - 14:20

Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses (PR) and one stable [...]

Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Haney to Executive Chairman

11/06/2024 - 14:15

BOSTON, June 11, 2024 (GLOBE NEWSWIRE) -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets, today announced the [...]

ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGY

11/06/2024 - 14:10

AGOURA HILLS, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will speak at the 20th Annual Congress of International Drug Discovery Science [...]

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

11/06/2024 - 14:00

- Topline data expected in December 2024 - - Phase 2b design optimized for success; clear path to market in this high value indication expected with positive result - BOSTON, June 11, 2024 (GLOBE NEWSWIRE) -- CervoMed [...]

Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001

11/06/2024 - 14:00

With Growing Body of Clinical Evidence, ALX-001 is Ready to Commence Phase 2 Studies NEW HAVEN, Conn., June 11, 2024 (GLOBE NEWSWIRE) -- Allyx Therapeutics, a clinical-stage biotechnology company working to deliver a [...]

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

10/06/2024 - 22:54

Iqirvo ® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver disease called primary biliary cholangitis Approval based on positive Phase III ELATIVE [...]

Le médicament Iqirvo® d’Ipsen obtient l’approbation de la FDA via une procédure accélérée comme traitement PPAR premier de sa classe thérapeutique pour la cholangite biliaire primitive

10/06/2024 - 22:54

Iqirvo® (elafibranor) 80 mg comprimés est le premier nouveau médicament approuvé depuis près de dix ans pour le traitement d’une maladie hépatique rare appelée cholangite biliaire primitive. L’approbation a été accordée [...]

ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering

10/06/2024 - 22:15

WINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today [...]